All In Biotech

Drug Trial Radar · NCT01263925

Prostaglandin E1 in Outpatients With Intermittent Claudication

Intravenous Prostaglandin E1 Treatment in Outpatients With Intermittent Claudication

Last checked: Nov 20, 2026Latest source record: Oct 27, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 561 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

561

Actual

Start

Apr 2001

Primary completion

Apr 2011

Study completion Apr 2011

Sponsor

Lead sponsor
UCB PharmaUCB
Sponsor type
Industry
First posted
Dec 21, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Investigate, under outpatient conditions, both the effect of 4 weeks of daily treatment with Prostaglandin E1 and that of 4 weeks of interval treatment (two infusions per week) on the pain-free walking distance in patients with Intermittent Claudication.

Conditions

  • Stage II Peripheral Arterial Occlusive Disease
  • Intermittent Claudication Fontaine Stage II PAOD

Interventions

  • Alprostadil (Prostaglandin E1)Drug

    4-week Daily Treatment Period 1: 4 weeks of 1 x daily intravenous infusion of 3 ampoules (20 µg) of Prostaglandin E1 (total 60 µg) in 50 - 250 ml physiological saline solution over 2 hours. 4-week Interval Treatment Period 2: 4 weeks of 2 x weekly intravenous infusion of 3 ampoules (20 µg) of Prostaglandin E1 (total 60 µg) in 50 - 250 ml physiological saline solution over 2 hours.

  • PentoxifyllineDrug

    4-week Daily Treatment Period 1: 4 weeks of 2 x daily (including weekends) 600 mg Pentoxifylline tablets. 4-week Interval Treatment Period 2: 4 weeks of 2 x daily (including weekends) 600 mg Pentoxifylline tablets.

  • Placebo to Pentoxifylline oralDrug

    4-week Daily Treatment Period 1: 4 weeks of 2 x daily (including weekends) matching Placebo to Pentoxifylline tablets. 4-week Interval Treatment Period 2: 4 weeks of 2 x daily (including weekends) matching Placebo to Pentoxifylline tablets.

  • Placebo to Alprostadil (Prostaglandin E1) intravenousDrug

    4-week Daily Treatment Period 1: 4 weeks of 1 x daily intravenous infusion of Placebo in 50 - 250 ml physiological saline solution over 2 hours. 4-week Interval Treatment Period 2: 4 weeks of 2 x weekly intravenous infusion of Placebo in 50 - 250 ml physiological saline solution over 2 hours.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ratio of Pain-free Walking Distance After Period 2 in Comparison With the Findings at BaselineTime frame: From Baseline to the end of 4 weeks of Interval Treatment (Period 2)
  2. Ratio of Pain-free Walking Distance After Period 3 in Comparison With the Findings at BaselineTime frame: From Baseline to the end of 6-months Follow-up (Period 3)
  3. Ratio of Pain-free Walking Distance After Period 1 in Comparison With the Findings at BaselineTime frame: From Baseline to the end of 4 weeks of Daily Treatment (Period 1)

Locations

36 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Aachen, Germany

  • Site not named

    Bad Säckingen, Germany

  • Site not named

    Berlin, Germany

  • Site not named

    Bottrop, Germany

  • Site not named

    Cologne, Germany

  • Site not named

    Dortmund, Germany

  • Site not named

    Dresden, Germany

  • Site not named

    Düsseldorf, Germany

  • Site not named

    Essen, Germany

  • Site not named

    Essen-Steele, Germany

  • Site not named

    Freiburg im Breisgau, Germany

  • Site not named

    Gaggenau, Germany

  • Site not named

    Görlitz, Germany

  • Site not named

    Hamburg, Germany

  • Site not named

    Hanover, Germany

  • Site not named

    Hattingen, Germany

  • Site not named

    Heidelberg, Germany

  • Site not named

    Homburg, Germany

  • Site not named

    Jena, Germany

  • Site not named

    Karlsbad-Lang Ensteinbach, Germany

  • Site not named

    Kassel, Germany

  • Site not named

    Krefeld, Germany

  • Site not named

    Leipzig, Germany

  • Site not named

    Lüneburg, Germany

  • Site not named

    Mannheim, Germany

  • Site not named

    Mannheim-Lindenhof, Germany

  • Site not named

    Mönchengladbach, Germany

  • Site not named

    München, Germany

  • Site not named

    Neuss, Germany

  • Site not named

    Nuremberg, Germany

  • Site not named

    Osnabrück, Germany

  • Site not named

    Papenburg, Germany

  • Site not named

    Regensburg, Germany

  • Site not named

    Seesen, Germany

  • Site not named

    Warendorf, Germany

  • Site not named

    Wuppertal, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.